Literature DB >> 28705008

Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.

Alex B Blair1, Lei Zheng2.   

Abstract

The complex interaction between the immune system, the tumor and the microenvironment in pancreatic ductal adenocarcinoma (PDA) leads to the resistance of PDA to immunotherapy. To overcome this resistance, combination immunotherapy is being proposed. However, rational combinations that target multiple aspects of the complex anti-tumor immune response are warranted. Novel clinical trials will investigate and optimize the combination immunotherapy for PDA.

Entities:  

Keywords:  GVAX; Immunotherapy; checkpoint inhibitors; combination immunotherapy; pancreatic cancer; vaccine therapy

Mesh：

Year:  2017        PMID： 28705008      PMCID： PMC6178804          DOI： 10.21037/cco.2017.06.04

Source DB:  PubMed          Journal:  Chin Clin Oncol        ISSN： 2304-3865


  57 in total

1.  Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

Authors:  Dung T Le; Andrea Wang-Gillam; Vincent Picozzi; Tim F Greten; Todd Crocenzi; Gregory Springett; Michael Morse; Herbert Zeh; Deirdre Cohen; Robert L Fine; Beth Onners; Jennifer N Uram; Daniel A Laheru; Eric R Lutz; Sara Solt; Aimee Luck Murphy; Justin Skoble; Ed Lemmens; John Grous; Thomas Dubensky; Dirk G Brockstedt; Elizabeth M Jaffee
Journal:  J Clin Oncol       Date:  2015-01-12       Impact factor: 44.544

2.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.

Authors:  Paolo P Provenzano; Carlos Cuevas; Amy E Chang; Vikas K Goel; Daniel D Von Hoff; Sunil R Hingorani
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

Review 3.  Xenotransplantation: the importance of the Galalpha1,3Gal epitope in hyperacute vascular rejection.

Authors:  D H Joziasse; R Oriol
Journal:  Biochim Biophys Acta       Date:  1999-10-08

4.  Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors.

Authors:  Edwin R Manuel; Jeremy Chen; Massimo D'Apuzzo; Melanie G Lampa; Teodora I Kaltcheva; Curtis B Thompson; Thomas Ludwig; Vincent Chung; Don J Diamond
Journal:  Cancer Immunol Res       Date:  2015-07-01       Impact factor: 11.151

5.  The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells.

Authors:  Francesca Fallarino; Ursula Grohmann; Sylvaine You; Barbara C McGrath; Douglas R Cavener; Carmine Vacca; Ciriana Orabona; Roberta Bianchi; Maria L Belladonna; Claudia Volpi; Pere Santamaria; Maria C Fioretti; Paolo Puccetti
Journal:  J Immunol       Date:  2006-06-01       Impact factor: 5.422

Review 6.  Evolving synergistic combinations of targeted immunotherapies to combat cancer.

Authors:  Ignacio Melero; David M Berman; M Angela Aznar; Alan J Korman; José Luis Pérez Gracia; John Haanen
Journal:  Nat Rev Cancer       Date:  2015-08       Impact factor: 60.716

7.  Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.

Authors:  Dung T Le; Eric Lutz; Jennifer N Uram; Elizabeth A Sugar; Beth Onners; Sara Solt; Lei Zheng; Luis A Diaz; Ross C Donehower; Elizabeth M Jaffee; Daniel A Laheru
Journal:  J Immunother       Date:  2013-09       Impact factor: 4.456

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.

Authors:  Aaron T Wild; Joseph M Herman; Avani S Dholakia; Shalini Moningi; Yao Lu; Lauren M Rosati; Amy Hacker-Prietz; Ryan K Assadi; Ali M Saeed; Timothy M Pawlik; Elizabeth M Jaffee; Daniel A Laheru; Phuoc T Tran; Matthew J Weiss; Christopher L Wolfgang; Eric Ford; Stuart A Grossman; Xiaobu Ye; Susannah G Ellsworth
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-12-01       Impact factor: 7.038

10.  Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.

Authors:  Hong Jiang; Samarth Hegde; Brett L Knolhoff; Yu Zhu; John M Herndon; Melissa A Meyer; Timothy M Nywening; William G Hawkins; Irina M Shapiro; David T Weaver; Jonathan A Pachter; Andrea Wang-Gillam; David G DeNardo
Journal:  Nat Med       Date:  2016-07-04       Impact factor: 53.440
View more
  6 in total

1.  The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor.

Authors:  Saber Amin; Michael Baine; Jane Meza; Morshed Alam; Chi Lin
Journal:  Clin Transl Radiat Oncol       Date:  2020-06-07

Review 2.  Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.

Authors:  Derya Kabacaoglu; Katrin J Ciecielski; Dietrich A Ruess; Hana Algül
Journal:  Front Immunol       Date:  2018-08-15       Impact factor: 7.561

Review 3.  Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment.

Authors:  Chin-King Looi; Felicia Fei-Lei Chung; Chee-Onn Leong; Shew-Fung Wong; Rozita Rosli; Chun-Wai Mai
Journal:  J Exp Clin Cancer Res       Date:  2019-04-15

4.  The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who received definitive surgery of the pancreatic tumor: a retrospective analysis of the National Cancer Database.

Authors:  Saber Amin; Michael Baine; Jane Meza; Morshed Alam; Chi Lin
Journal:  Radiat Oncol       Date:  2020-06-03       Impact factor: 3.481

Review 5.  The dark side of immunotherapy: pancreatic cancer.

Authors:  Gianluca Mucciolo; Cecilia Roux; Alessandro Scagliotti; Silvia Brugiapaglia; Francesco Novelli; Paola Cappello
Journal:  Cancer Drug Resist       Date:  2020-05-11

Review 6.  The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.

Authors:  Yaojie Fu; Shanshan Liu; Shan Zeng; Hong Shen
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.